Research digest · common questions
CJC-1295 FAQ: direct answers from the research
The questions people actually ask about CJC-1295 — safety, regulation, side effects, and the misconceptions — answered plainly and cited where the answer is quantitative.
If I take a peptide like CJC-1295 at 15, will I grow taller?
No. CJC-1295 raises growth hormone and IGF-1, but it does not lengthen bone once the growth plates have fused. In studied populations it acts on the GH/IGF-1 axis, not on adolescent height, and it is an unapproved research chemical rather than a growth treatment. Using an unstudied peptide in a teenager carries real, uncharacterized risk.
Is CJC-1295 safe?
Safety is not established. Human data are limited to early pharmacokinetic studies, the long-acting DAC program was discontinued, and FDA briefing materials cite immunogenicity and other concerns. Sustained growth-hormone and IGF-1 elevation raises theoretical questions about fluid retention, insulin sensitivity, and the IGF-1/cancer epidemiology. There is no long-term controlled human safety trial.
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog that signals the pituitary to release growth hormone. It is not an anabolic-androgenic steroid and works through an entirely different mechanism — the GHRH receptor and the GH/IGF-1 axis, not the androgen receptor.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use by the FDA or any major regulator; it is handled as a research chemical. It was reviewed at the FDA's 2024 Pharmacy Compounding Advisory Committee and was not recommended for the 503A compounding bulks list. It remains unapproved and is not eligible for pharmacy compounding.
Are CJC-1295 peptides safe?
Their safety is not established in controlled long-term human studies. Known and theoretical concerns include fluid retention, effects on insulin sensitivity, the IGF-1/cancer epidemiology, and immunogenicity flagged in FDA briefing materials. The published human record is limited to short-term pharmacokinetic work, not safety trials.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis, and the published CJC-1295 literature does not establish a direct effect on testosterone. Claims in either direction are not supported by controlled human data. The mechanism simply does not run through the hypothalamic-pituitary-gonadal pathway.
What are the side effects of CJC-1295?
Reported and theoretical effects tied to growth-hormone-axis stimulation include fluid retention and edema (growth hormone drives sodium reabsorption), injection-site reactions, effects on insulin sensitivity, and immunogenicity concerns raised in FDA briefing materials. Long-term human safety data are lacking, so the full side-effect profile is not characterized.
Does CJC-1295 lower testosterone?
There is no controlled-trial evidence that CJC-1295 lowers testosterone. It operates on the GH/IGF-1 axis rather than the hypothalamic-pituitary-gonadal axis, so a direct suppressive effect on testosterone is not something the literature supports.
Are peptides safer than TRT?
This is not answerable from the CJC-1295 evidence base. CJC-1295 is unapproved with limited human safety data, whereas testosterone replacement is an approved therapy with a defined risk profile. The two are not directly comparable on safety, and treating an unapproved research chemical as a safer alternative to an approved therapy is not supported.
How much CJC-1295 should I take?
There is no approved human dose. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram [1][3]; circulating community figures are not derived from controlled trials. This site reports research doses only and makes no recommendation.
How much CJC-1295 DAC should I take?
The DAC variant's multi-day half-life means a single dose elevates growth hormone and IGF-1 for days; pharmacokinetic studies dosed 30 to 90 micrograms per kilogram subcutaneously [1][3]. No human dosing is approved, and the protocols circulating online are not trial-derived.
What is CJC-1295 with DAC?
The DAC ('Drug Affinity Complex') form carries a maleimidopropionyl linker that covalently binds circulating serum albumin, extending the plasma half-life toward 5.8 to 8.1 days so a single dose acts for days [1][2]. That albumin bond is the defining feature of the long-acting form.
What is CJC-1295 DAC?
CJC-1295 DAC is the albumin-conjugated, long-acting version of the tetrasubstituted GHRH(1-29) analog. The albumin bond distinguishes it from the short-acting no-DAC 'Modified GRF 1-29' — same backbone, plus the linker that ties it to serum albumin [2].
How to reconstitute CJC-1295?
Research handling reconstitutes the lyophilized peptide with bacteriostatic water and refrigerates it; oral bioavailability is negligible. This is laboratory-handling context, not a use instruction. The handling notes describe how studies and suppliers store the peptide, nothing more.
Where to inject CJC-1295?
Studies used subcutaneous injection as the primary route [1][3][4]; early GRF(1-29) work also used the intravenous route [12]. This describes the routes studied in published research, not an administration recommendation for any individual.
How much CJC-1295 / ipamorelin should I take?
No approved human dose exists for either compound or the combination. The GHRH-analog-plus-GHRP pairing is studied for supra-additive growth-hormone release, but published human dosing data are limited and combination protocols are not trial-validated.
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life [1][2]. It is an unapproved research chemical, not an approved medicine.
What does CJC-1295 do?
In studied species it binds the GHRH receptor on pituitary somatotrophs and raises growth-hormone secretion, which in turn elevates liver-produced IGF-1, while preserving the natural pulsatile pattern of growth-hormone release [1][3]. The effect is sustained because of the long half-life.
Is CJC-1295 studied for anti-aging or longevity?
The interest stems from somatopause — the age-related decline in GH/IGF-1. GHRH-axis modulation has been proposed against sarcopenia [8], and related GHRH work has touched wound healing [9] and bone and skin endpoints in animals [10], but there is no controlled longevity trial of CJC-1295 itself.
Does CJC-1295 and ipamorelin work?
Mechanistically, GHRH analogs and GHRPs act on distinct receptors, and co-administration produces growth-hormone release greater than the sum of either alone. Direct controlled-trial efficacy data for the specific CJC-1295/ipamorelin combination in healthy adults are limited, so the synergy is established as pharmacology more than as a finished outcome study.
What is CJC-1295 ipamorelin?
It refers to combining CJC-1295 (a GHRH analog) with ipamorelin (a selective growth-hormone secretagogue, a GHRP) — a two-receptor pairing studied because the GHRH and ghrelin pathways synergize on growth-hormone release. It is a combination, not a single peptide.
What to expect when taking CJC-1295?
In studied subjects, CJC-1295 produced sustained, dose-dependent rises in growth hormone and IGF-1 over days [1][3]. Outside controlled studies, outcomes and safety are not characterized; this site summarizes research, not personal protocols, and CJC-1295 is not approved for human use.